Method for purifying beta-nicotinamide mononucleotide
View Patent ↗A method for purifying β-nicotinamide mononucleotide (NMN) includes: sequentially microfiltrating and nanofiltrating a crude product solution containing NMN using membrane concentration devices to obtain a concentrated crude product solution; adjusting the concentrated crude product solution to pH 3-7 to obtain a loading solution, loading the loading solution onto a preparative reverse phase high performance liquid chromatographic column, and purifying by gradient elution using an octadecylsilane-bonded silica gel as a stationary phase, a hydrochloric acid solution at pH 3-7 as a mobile phase A, and 100% ethanol as a mobile phase B, to obtain a purified sample solution; concentrating the purified sample solution by nanofiltration and freeze drying in a vacuum freeze drier to obtain a purified NMN.
1. A method for preparative purification of a salt of β-nicotinamide mononucleotide, comprising:
a. sequentially microfiltrating and nanofiltrating a crude product solution containing β-nicotinamide mononucleotide to obtain a concentrated crude product solution containing β-nicotinamide mononucleotide;
b. adjusting the concentrated crude product solution to pH 3-7 to obtain a loading solution, loading the loading solution onto a preparative reverse phase high performance liquid chromatographic column, and purifying a salt of β-nicotinamide mononucleotide by gradient elution with an octadecylsilane-bonded silica gel as a stationary phase, a hydrochloric acid solution at pH 3-7 as a mobile phase A, and 100% ethanol as a mobile phase B obtain a purified sample solution containing β-nicotinamide mononucleotide; and
c. concentrating the purified sample solution by nanofiltrating the purified sample solution to obtain a concentrated purified sample solution, and freeze drying the concentrated purified sample solution in a vacuum freeze drier to obtain a purified salt of β-nicotinamide mononucleotide.
2. The method according to claim 1 , wherein a membrane for the microfiltrating in Step a has a pore size of 0.2-1 μm.
3. The method according to claim 1 , wherein a membrane for the nanofiltrating in Step a has a 200 molecular weight cut-off.
4. The method according to claim 3 , wherein the membrane for the nanofiltrating in Step a is a hollow fiber membrane.
5. The method according to claim 1 , wherein the concentrated crude product solution in Step a contains 20-30 g/L of β-nicotinamide mononucleotide.
6. The method according to claim 1 , wherein the concentrated purified sample solution in Step c is 100-150 g/L of β-nicotinamide mononucleotide.
7. The method according to claim 1 , wherein a volume ratio of the mobile phase A to the mobile phase B in Step b is 2:98-1:1.
8. The method according to claim 1 , wherein a nanofiltration membrane for the nanofiltrating in Step c is a hollow fiber membrane with a 200 molecular weight cut-off.
9. The method according to claim 1 , wherein an elution time for the gradient elution in Step b is 40 min.